

The Tulane Cancer Center



THE TULANE CANCER CENTER

- Founded in 1993 as a resource for supporting cancer-focused basic research and clinical faculty, now with over 130 members
- Several areas of focus with national and international prominence, including clinical trials, prostate cancer, circadian biology, and DNA damage and repair
- Patients benefit from academic, multidisciplinary approach to care
- Excellent support system and training record for junior faculty, postdoctoral fellows, and graduate/undergraduate students
- Educates the general public about the critical link between basic research and disease prevention and treatment
- Multiple investigators focused on health disparities, especially in the Gulf South region

BASIC RESEARCH & CLINICAL CARE

Prostate Cancer Biology and Clinical Research/Trials

- Blends basic biology and translational research with drug trials, clinical research, and patient care
- Dr. Oliver Sartor, Medical Director of the Tulane Cancer Center, has been involved in clinical trials leading to the approval of six new prostate cancer treatments since 2010, and has served on the advisory committees for an additional four
- Strong clinical oncology program attracting patients for trials from 26 states and 7 countries, many with advanced or refractory disease
- Multiple basic scientists focused on prostate cancer biology, with special emphasis on the role of the androgen receptor in castration-resistant disease



Breast Cancer Research

- Strong emphasis on Triple Negative Breast Cancer, which disproportionately affects minority populations
- Full spectrum of disease is studied, using cellular and murine models paired with patient clinical data
- Working to understand origins of different types of breast cancers, including key transition points from benign to malignant tumors and the complex role of DNA repair mutations

Circadian Biology

- Nationally- and internationally-recognized research group focusing on the role of melatonin signaling in cancer
- Focus on basic biology of circadian disruption and carcinogenesis



BASIC RESEARCH & CLINICAL CARE (Continued)

Core Capacities: Clinical Trials & Second-Generation Sequencing Analysis

- Strong experience in clinical trials and recruitment for multiple cancer types
- Focus on the recruitment of minority and underrepresented patient populations
- Second-Generation Sequencing Analysis Core utilized by multiple investigators across different departments

DNA Damage, Repair, and Genomic Instability

- Large concentration of researchers focused on a variety of DNA damage and repair processes

Taking a Multi-Institute Collaborative Approach: The LCRC


- The Tulane Cancer Center is a partner member of the Louisiana Cancer Research Consortium, a unique public-private consortium made up of local universities and hospital systems
- Located in the Louisiana Cancer Research Center, a \$100M facility opened in 2013 housing labs from all member institutions, as well as clinical space
- Unique environment fosters collaboration across disciplines and institutions in state-of-the-art space

Clinical Care and Prevention Programs

- Hematopoietic Stem Cell Transplant Unit is only one of its kind in Louisiana
- Patients from all over the US and world receive comprehensive care, including nutritional and psychological support
- Unique therapy and advocate programs, including art therapy and patient-to-patient support networking
- Strong emphasis on prevention and screening for Breast, Prostate, and Skin Cancers

The Next Generation: Mentorship and Training

- Strong training record for junior faculty, postdoctoral fellows, graduate students, and undergraduate students, ensure the continuation of excellence in cancer research and care



BY THE NUMBERS:

129 Research Faculty Members

35 Clinicians

20 Postdoctoral Fellows, 33 Graduate Students, 12 Medical Fellows, and 6 Undergraduate Interns

\$10.5M in Annual Grant Dollars

1050 New Patients per Year from Across the US and Internationally

600 Patients Screened for Skin or Prostate Cancer in 2017

65 Open Clinical Trials with 305 New Patients (81% Caucasian, 17% African American, 2% Hispanic) Accrued in 2017

CONTACT & FURTHER INFO:



Prescott Deininger, PhD
Director, Tulane Cancer Center

+1 504.988.3068
pdeinin@tulane.edu

engage.tulane.edu